Home Catalogue search

eng

Refine your search:

Search in the Catalogues and Directories






	Sort by
Simple Search

Hits 1 – 8 of 8

1	Predictors of Poststroke Aphasia Recovery
	Bowen, A.; Williams, L.; Pavao Martins, I.. - : Ovid Technologies (Wolters Kluwer Health), 2021
	BASE
	Show details

2	Communicating simply, but not too simply: Reporting of participants and speech and language interventions for aphasia after stroke
	Mavis, I.; Kambanaros, M.; Mattioli, F.. - 2020
	BASE
	Show details

3	Creating an international, multidisciplinary, aphasia dataset of individual patient data (IPD) for the REhabilitation and recovery of peopLE with Aphasia after StrokE (RELEASE) project
	Williams, L.; Ali, M.; VandenBerg, K.. - 2016
	BASE
	Show details

4	A Benign Paroxysmal Positional Vertigo Specialty Clinic: A Model for Va Health Care
	Williams, L.; Akin, Faith W.; Hall, Courtney D....
	In: ETSU Faculty Works (2013)
	BASE
	Show details

5	Basal insulin and cardiovascular and other outcomes in dysglycemia.
	Gerstein, H.C.; Bosch, J.; Dagenais, G.R.; Díaz, R.; Jung, H.; Maggioni, A.P.; Pogue, J.; Probstfield, J.; Ramachandran, A.; Riddle, M.C.; Rydén, L.E.; Yusuf, S.
	In: New England Journal of Medicine, vol. 367, no. 4, pp. 319-328 (2012)
	Abstract: BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
	Keyword: Aged; Blood Glucose/analysis; Cardiovascular Diseases/epidemiology; Cardiovascular Diseases/etiology; Cholesterol/blood; Combination; Diabetes Mellitus; Double-Blind Method; Drug Therapy; Fasting; Fatty Acids; Female; Follow-Up Studies; Glucose Intolerance/complications; Glucose Intolerance/drug therapy; Hospitalization; Humans; Hypoglycemia/chemically induced; Hypoglycemic Agents/adverse effects; Hypoglycemic Agents/therapeutic use; Incidence; Insulin; Intention to Treat Analysis; Long-Acting/adverse effects; Long-Acting/therapeutic use; Male; Middle Aged; Omega-3/therapeutic use; Proportional Hazards Models; Triglycerides/blood; Type 2/complications; Type 2/drug therapy
	URL: https://doi.org/10.1056/NEJMoa1203858 https://serval.unil.ch/notice/serval:BIB_24F963809D9F
	BASE
	Hide details

6	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
	Bosch, J.; Gerstein, H.C.; Dagenais, G.R....
	In: New England Journal of Medicine, vol. 367, no. 4, pp. 309-318 (2012)
	BASE
	Show details

7	The child: Service needs, evaluation and intervention - Pre-school assessment project comparing assessment in the clinic or home
	Stewart, F.; Williams, L.
	In: International journal of language & communication disorders. - Oxford : Wiley-Blackwell 33 (1998), 520-525
	OLC Linguistik
	Show details

8	Phonetic variation as a function of second-language learning
	Williams, L.
	In: Perspectives in neurolinguistics, neuropsychology, and psycholinguistics (New York [etc.]), P.185-216
	MPI für Psycholinguistik
	Show details

© 2013 - 2024 Lin|gu|is|tik | Imprint | Privacy Policy | Datenschutzeinstellungen ändern